The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2020 | Optimism for amyloidosis therapy
Joel Buxbaum, MD, Scripps Research, La Jolla, CA, talks on improvements in amyloidosis management in recent years, commenting on the progression of options and outcomes in AL amyloidosis. Prof. Buxbaum goes on to discuss the issue of organ responses, specifically cardiac responses and recent advances such as the use of patisiran for the treatment of polyneuropathy in patients with hereditary transthyretin-mediated amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
